Armata Pharmaceuticals (ARMP) Total Current Liabilities (2013 - 2026)

Armata Pharmaceuticals (ARMP) has 14 years of Total Current Liabilities data on file, last reported at $9.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 91.65% year-over-year to $9.2 million; the trailing twelve-month figure through Mar 2026 stood at $9.2 million (down 91.65% YoY), and the FY2025 full-year result was $8.9 million, down 81.46% from the prior year.
• Total Current Liabilities advanced to $9.2 million in Q1 2026, from $8.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $140.0 million in Q3 2025 to a low of $6.2 million in Q1 2022.
• A 5-year average of $57.4 million and a median of $48.2 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 725.81% in 2023 and plunged 91.65% in 2026, its largest moves.
• Tracing ARMP's Total Current Liabilities over 5 years: stood at $24.9 million in 2022, then plunged by 33.82% to $16.5 million in 2023, then jumped by 193.11% to $48.2 million in 2024, then tumbled by 81.46% to $8.9 million in 2025, then climbed by 3.14% to $9.2 million in 2026.
• Business Quant data shows ARMP's Total Current Liabilities at $9.2 million in Q1 2026, $8.9 million in Q4 2025, and $140.0 million in Q3 2025.